Loading clinical trials...
Loading clinical trials...
A Randomized Phase II Study of Induction Chemotherapy Followed by Concurrent Chemoradiation Therapy According to EGFR Mutation Status in Patients With Unresectable Stage III NSCLC
Conditions
Interventions
Erlotinib
Induction or consolidation IP chemotherapy
+2 more
Locations
1
South Korea
National Cancer Center, Korea
Goyang-si, Gyenggi-do, South Korea
Start Date
February 1, 2008
Primary Completion Date
March 1, 2015
Completion Date
March 1, 2015
Last Updated
November 7, 2011
NCT07486219
NCT07190248
NCT07336732
NCT06305754
NCT05692635
NCT06498635
Lead Sponsor
National Cancer Center, Korea
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions